inclusion criteria: 1. have one or more of the following comorbidities: 1. age ≥ 65 years; 2. obesity (bmi ≥ 30); 3. hypertension (on one or more drugs for treatment of hypertension); 4. diabetes (on one or more drugs for type i or type ii diabetes); 5. cardiovascular disease (on one or more drugs for treatment of cardiovascular disease, other than aspirin); 6. history of congestive heart failure (chf) or myocardial infarction (mi); 7. black or african-american race (at least one parent identifies as black or african-american); 8. hispanic or latino ethnicity. 2. have a positive covid-19 test in the last 28 days; 3. have room air sao2 \< 96%, or spo2 \< 96% on room air at sea level, or pao2/fio2 \< 300; 4. have abnormal chest x-ray, mri or ct scan consistent with pulmonary complications from covid-19; 5. provide written informed consent prior to any study related procedures being performed.

inclusion criteria: 1. have one or more of the following comorbidities: 1. age ≥ 65 years; 2. obesity (bmi ≥ 30); 3. hypertension (on one or more drugs for treatment of hypertension); 4. diabetes (on one or more drugs for type i or type ii diabetes); 5. cardiovascular disease (on one or more drugs for treatment of cardiovascular disease, other than aspirin); 6. history of congestive heart failure (chf) or myocardial infarction (mi); 7. black or african-american race (at least one parent identifies as black or african-american); 8. hispanic or latino ethnicity. 2. have a positive covid-19 test in the last 28 days; 3. have room air sao2 \< 96%, or spo2 \< 96% on room air at sea level, or pao2/fio2 \< 300; 4. have abnormal chest x-ray, mri or ct scan consistent with pulmonary complications from covid-19; 5. provide written informed consent prior to any study related procedures being performed.

inclusion criteria: have one or more of the following comorbidities: age ≥ 65 years; obesity (bmi ≥ 30); hypertension (on one or more drugs for treatment of hypertension); diabetes (on one or more drugs for type i or type ii diabetes); cardiovascular disease (on one or more drugs for treatment of cardiovascular disease, other than aspirin); history of congestive heart failure (chf) or myocardial infarction (mi); black or african-american race (at least one parent identifies as black or african-american); hispanic or latino ethnicity. have a positive covid-19 test in the last 28 days; have room air sao2 < 96%, or spo2 < 96% on room air at sea level, or pao2/fio2 < 300; have abnormal chest x-ray, mri or ct scan consistent with pulmonary complications from covid-19; provide written informed consent prior to any study related procedures being performed.

inclusion criteria: have one or more of the following comorbidities: age ≥ 65 years; obesity (bmi ≥ 30); hypertension (on one or more drugs for treatment of hypertension); diabetes (on one or more drugs for type i or type ii diabetes); cardiovascular disease (on one or more drugs for treatment of cardiovascular disease, other than aspirin); history of congestive heart failure (chf) or myocardial infarction (mi); black or african-american race (at least one parent identifies as black or african-american); hispanic or latino ethnicity. have a positive covid-19 test in the last 28 days; have room air sao2 < 96%, or spo2 < 96% on room air at sea level, or pao2/fio2 < 300; have abnormal chest x-ray, mri or ct scan consistent with pulmonary complications from covid-19; provide written informed consent prior to any study related procedures being performed.

inclusion criteria: 1. have one or more of the following comorbidities: 1. age ≥ 65 years; 2. obesity (bmi ≥ 30); 3. hypertension (on one or more drugs for treatment of hypertension); 4. diabetes (on one or more drugs for type i or type ii diabetes); 5. cardiovascular disease (on one or more drugs for treatment of cardiovascular disease, other than aspirin); 6. history of congestive heart failure (chf) or myocardial infarction (mi); 7. black or african-american race (at least one parent identifies as black or african-american); 8. hispanic or latino ethnicity. 2. have a positive covid-19 test in the last 28 days; 3. have room air sao2 < 96%, or spo2 < 96% on room air at sea level, or pao2/fio2 < 300; 4. have abnormal chest x-ray, mri or ct scan consistent with pulmonary complications from covid-19; 5. provide written informed consent prior to any study related procedures being performed.

inclusion criteria: 1. have one or more of the following comorbidities: 1. age ≥ 65 years; 2. obesity (bmi ≥ 30); 3. hypertension (on one or more drugs for treatment of hypertension); 4. diabetes (on one or more drugs for type i or type ii diabetes); 5. cardiovascular disease (on one or more drugs for treatment of cardiovascular disease, other than aspirin); 6. history of congestive heart failure (chf) or myocardial infarction (mi); 7. black or african-american race (at least one parent identifies as black or african-american); 8. hispanic or latino ethnicity. 2. have a positive covid-19 test in the last 28 days; 3. have room air sao2 < 96%, or spo2 < 96% on room air at sea level, or pao2/fio2 < 300; 4. have abnormal chest x-ray, mri or ct scan consistent with pulmonary complications from covid-19; 5. provide written informed consent prior to any study related procedures being performed.

inclusion criteria: 1. have one or more of the following high risk factors: 1. age ≥ 65 years; 2. obesity (bmi ≥ 30); 3. hypertension (on one or more drugs for treatment of hypertension); 4. diabetes (on one or more drugs for type i or type ii diabetes); 5. cardiovascular disease (on one or more drugs for treatment of cardiovascular disease, other than aspirin); 6. history of congestive heart failure (chf) or myocardial infarction (mi) diagnosed in the last 3 months; 7. black or african-american race (at least one parent identifies as black or african-american); 8. hispanic or latino ethnicity. 2. have a positive covid-19 test in the last 28 days; 3. have room air sao2 <94%; 4. have abnormal chest x-ray, mri or ct scan consistent with pulmonary complications from covid-19; 5. provide written informed consent prior to any study related procedures being performed.

inclusion criteria: 1. have one or more of the following high risk factors: 1. age ≥ 65 years; 2. obesity (bmi ≥ 30); 3. hypertension (on one or more drugs for treatment of hypertension); 4. diabetes (on one or more drugs for type i or type ii diabetes); 5. cardiovascular disease (on one or more drugs for treatment of cardiovascular disease, other than aspirin); 6. history of congestive heart failure (chf) or myocardial infarction (mi) diagnosed in the last 3 months; 7. black or african-american race (at least one parent identifies as black or african-american); 8. hispanic or latino ethnicity. 2. have a positive covid-19 test in the last 28 days; 3. have room air sao2 <94%; 4. have abnormal chest x-ray, mri or ct scan consistent with pulmonary complications from covid-19; 5. provide written informed consent prior to any study related procedures being performed.